Literature DB >> 1647334

Basal and insulin stimulated substrate metabolism in tumour induced hypoglycaemia; evidence for increased muscle glucose uptake.

N Møller1, W F Blum, A Mengel, L B Hansen, K G Alberti, O Schmitz.   

Abstract

While it has very recently been reported that tumour induced hypoglycaemia is characterised by elevated production of insulin-like growth factor 2, the tissues responsible for induction of hypoglycaemia are largely unknown. We have investigated a patient with a large retroperitoneal mass and spontaneous hypoglycaemia. When compared to a reference population the patient displayed: (1) An increased glucose disposal rate and a five-fold elevation of forearm glucose uptake. (2) A decreased endogenous glucose production rate. (3) Decreased circulating levels of lipid intermediates. (4) Increased glucose oxidation and decreased lipid oxidation. (5) Low circulating levels of insulin-like growth factor 2 and insulin-like growth factor-binding protein-3 and normal levels of insulin-like growth factor 1. (6) Normal insulin sensitivity (euglycaemic glucose clamp). Blood concentrations of insulin, C-peptide, proinsulin, glucagon, growth hormone and catecholamines were within normal range, but the growth hormone response to hypoglycaemia was blunted. The data suggest that the mechanisms behind tumour induced hypoglycaemia are of systemic nature and that the tissue most prominently affected is striated muscle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1647334     DOI: 10.1007/bf00404019

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  21 in total

1.  EVIDENCE FAVORING THE SARCOMATOUS ORIGIN OF AN INSULIN-LIKE SUBSTANCE IN A CASE OF FIBROSARCOMA WITH HYPOGLYCEMIA.

Authors:  R VOLPE; J EVANS; D W CLARKE; N FORBATH; R EHRLICH
Journal:  Am J Med       Date:  1965-04       Impact factor: 4.965

2.  FIBRO-SARCOMA OF THE MEDIASTINUM.

Authors:  K W Doege
Journal:  Ann Surg       Date:  1930-11       Impact factor: 12.969

3.  Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man.

Authors:  N Møller; J O Jørgensen; K G Alberti; A Flyvbjerg; O Schmitz
Journal:  J Clin Endocrinol Metab       Date:  1990-04       Impact factor: 5.958

4.  A simple and ultrasensitive method for determination of free fatty acid by radiochemical assay.

Authors:  R J Ho; H C Meng
Journal:  Anal Biochem       Date:  1969-10-01       Impact factor: 3.365

5.  Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type 1 (insulin-dependent) diabetes.

Authors:  O Hother-Nielsen; O Schmitz; J Bak; H Beck-Nielsen
Journal:  Diabetologia       Date:  1987-11       Impact factor: 10.122

6.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency.

Authors:  W F Blum; M B Ranke; K Kietzmann; E Gauggel; H J Zeisel; J R Bierich
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

7.  Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia.

Authors:  W H Daughaday; M A Emanuele; M H Brooks; A L Barbato; M Kapadia; P Rotwein
Journal:  N Engl J Med       Date:  1988-12-01       Impact factor: 91.245

8.  Isolation and partial characterization of six somatomedin-like peptides from human plasma Cohn fraction IV.

Authors:  W F Blum; M B Ranke; J R Bierich
Journal:  Acta Endocrinol (Copenh)       Date:  1986-02

9.  A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I.

Authors:  W F Blum; M B Ranke; J R Bierich
Journal:  Acta Endocrinol (Copenh)       Date:  1988-07

10.  Measurement of somatomedin-related peptides in fetal, neonatal, and maternal rat serum by insulin-like growth factor (IGF) I radioimmunoassay, IGF-II radioreceptor assay (RRA), and multiplication-stimulating activity RRA after acid-ethanol extraction.

Authors:  W H Daughaday; K A Parker; S Borowsky; B Trivedi; M Kapadia
Journal:  Endocrinology       Date:  1982-02       Impact factor: 4.736

View more
  5 in total

Review 1.  Recombinant human IGF-1 (insulin-like growth factor) therapy: where do we stand today?

Authors:  Bharti Balhara; Madhusmita Misra; Lynne L Levitsky
Journal:  Indian J Pediatr       Date:  2011-11-17       Impact factor: 1.967

2.  Can "big" insulin-like growth factor II in serum of tumor patients account for the development of extrapancreatic tumor hypoglycemia?

Authors:  J Zapf; E Futo; M Peter; E R Froesch
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

3.  Glucose utilization in a patient with hepatoma and hypoglycemia. Assessment by a positron emission tomography.

Authors:  R C Eastman; R E Carson; D G Orloff; C S Cochran; J F Perdue; M M Rechler; F Lanau; C T Roberts; J Shapiro; J Roth
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

4.  Exome sequencing revealed DNA variants in NCOR1, IGF2BP1, SGLT2 and NEK11 as potential novel causes of ketotic hypoglycemia in children.

Authors:  Yazeid Alhaidan; Martin J Larsen; Anders Jørgen Schou; Maria H Stenlid; Mohammed A Al Balwi; Henrik Thybo Christesen; Klaus Brusgaard
Journal:  Sci Rep       Date:  2020-02-07       Impact factor: 4.379

5.  Metastatic secondary fibrosarcoma of bone responsive to repeated courses of Ifosfamide and associated with hypoglycemia.

Authors:  Elaine S Bouttell; N Wilson Rodger; Vivien H C Bramwell
Journal:  Sarcoma       Date:  2003
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.